The blood–brain barrier (BBB) continues to be
one of the
main clinical obstacles in the treatment of glioma. Current chemotherapies
always bring many different side effects, some even permanent. To
date, nanomaterial-based vehicles have shown great potential in treating
glioma. Herein, we developed a dual targeting liposomal delivery vector
loaded with the anticancer drug doxorubicin (DOX) to treat glioma.
SS31, a small peptide, has shown dual targeting effects of penetrating
the BBB and specifically targeting mitochondria. In this study, a
new liposomal delivery system, LS-DOX, was prepared by modifying DOX-loaded
liposomes with SS31 for the treatment of in situ glioma. The liposomes
demonstrated a high drug encapsulation rate and drug-loading capacity,
satisfactory biocompatibility, high glioma accumulation ability, and
good stability in vitro. Experimental results showed that the liposomes
could effectively cross the BBB and target gliomas, and mitochondria-targeting
of SS31 enhances cell uptake. In addition, the liposomes showed a
good therapeutic effect on nude mice with glioma in situ with no obvious
toxicity and side effects. Therefore, the present research will provide
a novel alternative and reference for the effective treatment of glioma.